Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX Briacell Therap	$2.96 +0.9%	$3.43	$2.78 ▼ $29.40	$19.93M	1.27	569,808 shs	3,058 shs
CTMX CytomX Therapeutics	$2.47 -0.4%	$1.99	$0.40 ▼ $3.10	$200.74M	2.05	2.18 million shs	2,382 shs
OPTN OptiNose	$9.60	$9.54	$4.82 ▼ $19.50	$97.22M	-0.88	62,510 shs	N/A
UNCY Unicycive Therapeutics	$4.37 -5.9%	$6.30	$2.02 ▼ $11.00	$56.02M	1.89	262,862 shs	54,379 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX Briacell Therap	+2.45%	0.00%	-15.56%	-16.29%	-80.66%
CTMX CytomX Therapeutics	+5.08%	+12.22%	-1.20%	+356.64%	+87.88%
OPTN OptiNose	0.00%	0.00%	0.00%	+5.03%	-38.46%
UNCY Unicycive Therapeutics	-5.31%	-25.28%	-29.95%	-21.36%	-3.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCTX Briacell Therap	3.0694 of 5 stars	3.5	5.0	0.0	3.1	0.0	0.6
CTMX CytomX Therapeutics	4.385 of 5 stars	3.5	1.0	4.7	3.5	1.7	1.3
OPTN OptiNose	0.6741 of 5 stars	1.0	0.0	4.2	0.6	1.7	0.6
UNCY Unicycive Therapeutics	3.1426 of 5 stars	3.8	3.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX Briacell Therap	3.00	Buy	$32.00	982.91% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	115.92% Upside
OPTN OptiNose	2.00	Hold	$9.00	-6.25% Downside
UNCY Unicycive Therapeutics	3.50	Strong Buy	$60.00	1,274.57% Upside

Current Analyst Ratings Breakdown

Latest BCTX, CTMX, UNCY, and OPTN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/19/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $9.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/22/2025	BCTX Briacell Therap	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/21/2025	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
4/11/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$1.76 per share	N/A
CTMX CytomX Therapeutics	$138.10M	1.44	$0.38 per share	6.52	($0.01) per share	-247.00
OPTN OptiNose	$81.86M	1.19	N/A	N/A	($11.56) per share	-0.83
UNCY Unicycive Therapeutics	$680K	81.14	N/A	N/A	$0.72 per share	6.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX Briacell Therap	-$4.79M	-$8.32	N/A	N/A	N/A	N/A	-479.97%	-182.26%	N/A
CTMX CytomX Therapeutics	$31.87M	$0.48	5.19	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
OPTN OptiNose	-$35.48M	-$3.00	N/A	N/A	N/A	-41.16%	N/A	-27.42%	8/6/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest BCTX, CTMX, UNCY, and OPTN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q3 2025	BCTX Briacell Therap	-$1.76	-$1.64	+$0.12	-$1.64	N/A	N/A
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$1.40	-$0.50	+$0.90	-$0.05	N/A	N/A
5/13/2025	Q1 2025	OPTN OptiNose	-$0.74	-$1.01	-$0.27	-$1.92	$17.70 million	$18.51 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX Briacell Therap	N/A	3.41	3.41
CTMX CytomX Therapeutics	N/A	1.73	1.73
OPTN OptiNose	N/A	0.79	0.72
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX Briacell Therap	15.42%
CTMX CytomX Therapeutics	67.77%
OPTN OptiNose	85.60%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
BCTX Briacell Therap	5.73%
CTMX CytomX Therapeutics	6.60%
OPTN OptiNose	2.30%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX Briacell Therap	8	6.78 million	6.39 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
OPTN OptiNose	190	10.13 million	9.83 million	Not Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

BCTX, CTMX, UNCY, and OPTN Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 2 at 10:00 AM | prnewswire.com

Unicycive hit with CRL on oxylanthanum carbonate NDA

July 1 at 3:25 PM | thepharmaletter.comT

Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

July 1 at 4:36 AM | theglobeandmail.com

Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance

June 30 at 11:36 PM | finance.yahoo.com

FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect

June 30 at 6:35 PM | fiercepharma.comF

Unicycive receives CRL for oxylanthanum carbonate NDA for hyperphosphatemia

June 30 at 6:35 PM | msn.com

Unicycive stock falls after FDA issues Complete Response Letter

June 30 at 6:35 PM | investing.com

Unicycive Shares Slide Premarket as FDA Rejects Oxylanthanum Carbonate Application

June 30 at 6:35 PM | marketwatch.com

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease ...

June 30 at 6:35 PM | finance.yahoo.com

Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing

June 30 at 6:35 PM | msn.com

INVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLC

June 30 at 12:58 PM | globenewswire.com

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 30 at 7:05 AM | globenewswire.com

Unicycive Therapeutics Inc News (UNCY) - Investing.com

June 24, 2025 | investing.com

Unicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down - Time to Sell?

June 20, 2025 | marketbeat.com

Unicycive Therapeutics Inc trading halted, news pending

June 18, 2025 | msn.com

Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing

June 18, 2025 | investing.com

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

June 17, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in May

June 15, 2025 | marketbeat.com

UNCY Q3 EPS Forecast Raised by Brookline Capital Management

June 12, 2025 | marketbeat.com

Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations

June 11, 2025 | theglobeandmail.com

Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m

June 11, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX, CTMX, UNCY, and OPTN Company Descriptions

Briacell Therap NASDAQ:BCTX

$2.96 +0.03 (+0.85%)

As of 09:47 AM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

CytomX Therapeutics NASDAQ:CTMX

$2.47 -0.01 (-0.40%)

As of 09:48 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)

As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Unicycive Therapeutics NASDAQ:UNCY

$4.36 -0.28 (-5.93%)

As of 09:49 AM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time